Wang CC 2005.

Methods	Country: China Setting: hospital based Aim: to study the effects of Gumikang capsule in the treatment of postmenopausal osteoporosis Study design: randomised controlled trial Analysis: T‐test, Chi2 test Loss to follow‐up: not reported
Participants	Ethnicity: Chinese 60 postmenopausal osteoporosis patients enrolled: 32 in trial group, 28 in control group Inclusion criteria: Chinese diagnostic criteria for osteoporosis, BMD detected by DXA Exclusion criteria: metabolic disease, endocrine disease
Interventions	Experimental: Gumikang capsule, 5 capsules, twice a day, for 6 months Control: calcium gluconate, 500 mg, 3 times a day, for 6 months
Outcomes	BMD, E2, Ca, ALP
Notes	No funding sources or declarations of interest for the primary researchers reported
Risk of bias
Bias	Authors' judgement	Support for judgement
Adequate sequence generation	Unclear risk	No information provided
Allocation concealment	Unclear risk	No information provided
Blinding All outcomes	Unclear risk	Insufficient information to permit judgement of 'low risk' or 'high risk'
Incomplete outcome data addressed All outcomes	Low risk	No missing outcome data
Free of selective reporting	Unclear risk	Not all the outcomes that were of interest in this review were reported
Free of other bias	Low risk	The study appears to be free of other sources of bias